💨 Abstract

Ricardo Teijeiro, an infectologist, discussed the Argentine vaccine ARVAC on CNN Radio Argentina. ARVAC is effective against new COVID-19 variants, including JN.1, and can be modified to target circulating strains. Teijeiro emphasized the importance of completing the primary vaccination series and maintaining updated booster shots. ARVAC, a protein-based vaccine developed with genetic engineering, is cost-effective and comparable in efficacy to other vaccines.

Courtesy: WTOP Staff